publication venue for
- Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies. 17:1-8. 2024
- Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases. 17:39-45. 2024
- Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders. 16:55-70. 2023
- Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science. 16:87-106. 2023
- High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. 12:685-698. 2019
- Switching patients in the age of long-acting recombinant products?. 12:1-13. 2019
- Andexanet alfa for the treatment of hemorrhage. 11:847-855. 2018
- Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials. 11:37-44. 2018
- The current state of adverse event reporting in hemophilia. 10:161-168. 2017
- Thrombosis in pediatric cancer: identifying the risk factors to improve care. 6:599-609. 2013
- Preventing thrombophilia-related complications of pregnancy: an update. 6:287-300. 2013
- Treatment of warfarin-associated coagulopathy with vitamin K. 4:657-667. 2011
- Quebec platelet disorder. 4:137-141. 2011
- Fondaparinux: does it cause HIT? can it treat HIT?. 3:567-581. 2010
- Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage. 2:357-360. 2009
- Preventing thrombophilia-related complications of pregnancy. 2:183-196. 2009
- Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. 1:75-85. 2008